Stem cell‐based and mesenchymal stem cell derivatives for coronavirus treatment
- 23 September 2021
- journal article
- review article
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 69 (5) , 1942-1965
Abstract
Coronavirus disease 2019 (COVID-19) as one of the diseases pneumonia was first reported in Wuhan, China in December 2019. COVID-19 is considered the third most common coronavirus among individuals after acute respiratory syndrome (SARS-CoV) and the Middle East respiratory syndrome (MERS-CoV) in the 20th century. Many studies have shown that cell therapy and regenerative medicine approaches have an impressive effect on different dangerous diseases in a way that using a cell-based experiment could be effective for improving humans with severe acute respiratory infections caused by the 2019 novel coronavirus. Accordingly, due to the stunning effects of mesenchymal stem cells and derivatives on the treatment of various diseases, this review focuses on the auxiliary role of mesenchymal stem cells and their derivatives in reducing the inflammatory processes of acute respiratory infections resulted from the 2019 novel coronavirus. The reported MSCs treatment outcomes are significant because these cells prevent the immune system from over-activating and improve, endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection. The MSCs can be an effective, autologous, and safe treatment, and therefore, share the results. To date, the results of several studies have shown that mesenchymal stem cells and their derivatives can inhibit inflammation. Exosomes act as intercellular communication devices between cells for the transfer of active molecules. In this review, recent mesenchymal stem cells and their derivatives-based clinical trials for the cure of COVID-19 are introduced. This article is protected by copyright. All rights reservedKeywords
This publication has 73 references indexed in Scilit:
- Mesenchymal Stem Cells in Tissue RepairFrontiers in Immunology, 2013
- Leukemia Inhibitory Factor Signaling Is Required for Lung Protection during PneumoniaThe Journal of Immunology, 2012
- Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6Stem Cell Research & Therapy, 2011
- Potential application of mesenchymal stem cells in acute lung injuryExpert Opinion on Biological Therapy, 2009
- Coronaviruses post-SARS: update on replication and pathogenesisNature Reviews Microbiology, 2009
- Human immunopathogenesis of severe acute respiratory syndrome (SARS)Virus Research, 2008
- Prevention of LPS-Induced Acute Lung Injury in Mice by Mesenchymal Stem Cells Overexpressing Angiopoietin 1PLOS Medicine, 2007
- Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferationBlood, 2006
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003